Bollard Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bollard Group’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5	Closed	-$2K	–	398
2023 Q2	$2K	Buy	+5	New	+$2.04K	﹤0.01%	505

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bollard Group's BIO Position: Q3 2023 in Review

Bollard Group sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2023, closing a stake of 5 shares — an estimated $2K sold.

Bollard Group first reported a position in BIO in Q2 2023 and held it in 1 quarter. The position peaked at $2K in Q2 2023. 467 funds tracked by Wall St. Rank hold BIO as of Q3 2023.

Bollard Group reported no remaining Bio-Rad Laboratories Class A position as of Q3 2023 after selling out during the quarter.
Bollard Group sold 5 Bio-Rad Laboratories Class A shares in Q3 2023, an estimated $2K.
Bollard Group first reported a position in Bio-Rad Laboratories Class A in Q2 2023 and held it in 1 quarter.
Bollard Group's Bio-Rad Laboratories Class A position peaked at $2K in Q2 2023.
467 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2023.

Based on Bollard Group's 13F filing for Q3 2023, filed 14 Nov 2023.